Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Inventory (2016 - 2025)

IGC Pharma has reported Inventory over the past 14 years, most recently at $658000.0 for Q3 2025.

  • Quarterly Inventory fell 56.42% to $658000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $658000.0 through Sep 2025, down 56.42% year-over-year, with the annual reading at $1.4 million for FY2025, 11.69% down from the prior year.
  • Inventory was $658000.0 for Q3 2025 at IGC Pharma, down from $1.3 million in the prior quarter.
  • Over five years, Inventory peaked at $5.5 million in Q3 2021 and troughed at $15000.0 in Q3 2023.
  • The 5-year median for Inventory is $1.5 million (2024), against an average of $1.9 million.
  • Year-over-year, Inventory crashed 99.6% in 2023 and then surged 9966.67% in 2024.
  • A 5-year view of Inventory shows it stood at $511000.0 in 2021, then tumbled by 89.24% to $55000.0 in 2022, then surged by 3400.0% to $1.9 million in 2023, then dropped by 25.56% to $1.4 million in 2024, then tumbled by 54.08% to $658000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Inventory are $658000.0 (Q3 2025), $1.3 million (Q2 2025), and $1.4 million (Q1 2025).